BioPharma Today

Season's Greetings (Oh Yes, And A Gift Too!)

We wish all our readers a joyful holiday season and all the best for 2010. BioPharma Today will resume publishing in the new year. As a small token of thanks for your support this year, we'd like to offer you a complimentary issue of The RPM Report!

Latest News from "The Pink Sheet" DAILY

AstraZeneca Takes Out Antibiotic Firm Novexel, With Cash Back from Forest

Editors' Picks from the World Press

Pipeline/RD News

• Bacterial cellulose could help develop synthetic blood vessels

Coming in Thursday's "The Pink Sheet" DAILY

AstraZeneca acquires antibiotic developer Novexel for $350 million in cash plus $75 million in post-deal milestones.

Latest News From "The Pink Sheet" DAILY

Silence-Intradigm Deal is Only Year-End Noise on Quiet RNAi Front

Editors' Picks from the World Press

Pipeline/RD News

• Study: C-reactive protein is sign, not cause of heart attacks

Introducing BioPharma Today's LinkedIn Group - Join Today!

If you belong to LinkedIn, we would like to invite you to join a new group we have launched for BioPharma Today.

Coming in Wednesday's "The Pink Sheet" DAILY

The FDA action date for a label expansion of sleep drug Nuvigil was pushed back 90 days to March 29, 2010, because the sponsor, Cephalon, had submitted additional information within 90 days of the prior PDUFA date.

Latest News from "The Pink Sheet" DAILY

With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis

No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.   read more

 

Health Reform Home Stretch: Revised Senate Bill Includes Clinical Trial Coverage Mandate

Manager's amendment passes key procedural hurdle.   read more

 

Sanofi-Aventis Will Enter U.S. OTC Market By Paying $1.9 Billion For Chattem

The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.   read more

 

Merck Hires Julie Gerberding, A Former CDC Chief, To Run Its Vaccine Division

The big drug maker hires a high-profile physician with a public-health pedigree to boost its stagnant vaccine division.   read more

 

Seattle Genetics, GSK in Next-Generation Antibody Deal

Seattle Genetics' third deal in two months signals big pharma's growing interest in antibody conjugate technology or "empowered" antibodies for immunotherapies targeting cancer and other hard-to-treat diseases.   read more

 

Pfizer Licenses Athersys' Stem Cell Technology For IBD Drug Development

Following the deal news, Athersys' stock price soared during same-day trading.   read more

 

Selling Comparative Effectiveness: Practice May Need Positive Branding

Professional advertisers might be needed to sell a positive comparative effectiveness research message, industry observer says.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here

 

Editors' Picks from the World Press

Pipeline/RD News

• Cimzia misses goals of late-stage trial for Crohn's disease
• Protein plays role in Type 2 diabetes, scientists find
• Protein-based avian flu vaccine to enter midstage trial
• Sanofi-Aventis discontinues work on 2 drugs

Business Finance

• Merck taps former CDC chief to lead vaccine operations
• OncoGenex licenses experimental cancer drug to Teva
• Seattle Genetics licenses technology to GSK
• Incyte sells rights to anti-inflammatory drug to Lilly

Government Legal News

• Pixantrone gets orphan-drug status from European regulator
• Sandoz' generic Nimbex triggers patent rift with Abbott
• FDA delays decision on wider use of Cephalon's Nuvigil